Evidence map›Paper›PMID 40874184›Full record

ArticleOpen forum infectious diseases2025

Factors Predictive of Early Discontinuation of Preventive Treatment in Children With Household Exposure to Multidrug-resistant Tuberculosis.

Trinh Duong, Joanna Brigden, Susan E Purchase, Neil A Martinson, Lee Fairlie, Suzanne Staples, Faeezah Patel, Nadia Sabet, Charlotte Layton, Thomas Wilkinson and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Trinh DuongInstitute of Clinical Trials and Methodology, Faculty of Population Health Sciences, University College London, London, UK.ORCID https://orcid.org/0000-0002-1328-1310
Joanna BrigdenInstitute of Clinical Trials and Methodology, Faculty of Population Health Sciences, University College London, London, UK.
Susan E PurchaseDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.
Neil A MartinsonPerinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
Lee FairlieWits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Suzanne StaplesTuberculosis & HIV Investigative Network, Research Department, Durban, South Africa.
Faeezah PatelWits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Nadia SabetPerinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
Charlotte LaytonInstitute of Clinical Trials and Methodology, Faculty of Population Health Sciences, University College London, London, UK.
Thomas WilkinsonHealth Economics Unit, University of Cape Town, Cape Town, South Africa.ORCID https://orcid.org/0000-0003-0806-2196
H Simon SchaafDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.
James A SeddonDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.
Anneke C HesselingDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The World Health Organization recommended levofloxacin for tuberculosis (TB) preventive treatment for child and adult contacts of multidrug-resistant TB. Method: TB-CHAMP (ISRCTN92634082) was a double-blind community-based multisite randomized placebo-controlled trial assessing levofloxacin as preventive treatment in children with household exposure to adults with microbiologically confirmed multidrug-resistant TB in South Africa. Households were randomized 1:1 to 24 weeks of daily levofloxacin (adult scored 250-mg tablets) versus placebo. Treatment adherence was ascertained through pill counts and treatment cards. Competing risk methods were used to assess factors associated with early treatment discontinuation for nonclinical reasons before achieving ≥80% of allocated doses (adequate treatment). Results: Among 911 of 922 children included in analysis, 90% were younger than 5 years of age. Overall, 765 (84%) of children achieved adequate treatment, 135 (15%) discontinued treatment early, and 11 (1%) had not achieved adequate treatment by the end-of-treatment period. Sixty-four (7%) children stopped for clinical reasons and 71 (8%) for nonclinical reasons, with similar proportions across treatment groups. Baseline factors associated with early treatment discontinuation for nonclinical reasons were previous receipt of herbal/traditional medicine (subhazard ratio 3.08; 95% confidence interval, 1.69-5.59; Conclusions: Adherence to the 250-mg levofloxacin formulation was good among young children on preventive TB therapy. Adherence support for children and caregivers, and addressing early signs of poor adherence, may enhance treatment completion.

Indexed as

adherencechildrenlevofloxacinmultidrug-resistant tuberculosispreventive treatment

Identifiers

PMID40874184
PMCPMC12378377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.